On February 10, 2021 AbClon reported that the company will participate in the "CAR-TCR Europe Summit" (Press release, AbClon, FEB 10, 2021, View Source;wr_id=131&page=4 [SID1234638628]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AT101 CD19 targets disease protein B As a treatment for cell-derived blood cancer, existing CD19 CAR-T shows anticancer effect AT101 For the model)Yescata, etc., , AT101. is seeking differentiation by developing new humanized antibodies with completely different action sites, while ​FMC63Cell therapy uses mouse-derived antibodies.

AT501is HER2 an ovarian cancer treatment targeting disease protein, This is a material applied with AbClone’s original technology Switchable CAR-T (zCAR-T) . By controlling the concentration of the switch substance administered in the body CAR-T is a mechanism that regulates the activity of cells. CAR-T Disadvantage of cell therapy ​CRS (Cytokine Release Syndrome) It is possible to structurally overcome. In addition, , its platform nature has been strengthened as cross-application is possible for various cancer types by changing the switch material. Innovation CAR-T is a cell therapy.